Physician profile
Alberto Guardiola
NPI 1144426230
$1,418.97
in general payments reported to CMS, 2019-2025
11 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $19.36 · 2021: $143 · 2022: $426 · 2023: $235 · 2024: $273 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $330.49 | 2021-2024 | Acthar |
| Alcon Puerto Rico INC | $310.26 | 2022-2025 | Unity, Clareon |
| Genentech USA, INC. | $304.33 | 2022-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $206.50 | 2019-2022 | |
| Allergan, INC. | $69.33 | 2020-2021 | |
| Alcon Vision LLC | $51.93 | 2024 | Clareon |
| Apellis Pharmaceuticals, INC. | $50.42 | 2022-2023 | Syfovre |
| Genentech, INC. | $25.64 | 2024 | Vabysmo |
| Novo Nordisk INC | $25.00 | 2022 | |
| Horizon Therapeutics Plc | $23.43 | 2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $21.64 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Guardiola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.